ERNA Eterna Therapeutics: Utang jangka cendhak perusahaan

Eterna Therapeutics (ERNA) possesses a powerful defensive moat driven by unique genome editing patents and stringent FDA requirements. Its status as the exclusive creator of blood-based RNA correction methods provides the business with full pricing power over the future cost of therapy, which currently stands at 0.00. This price chart on GURU.Markets complements data regarding production via external CMO facilities, which minimize equipment expenditures.

This indicator aggregates the total of all current liabilities with a maturity of up to one year, allowing for an assessment of liquidity risk and dependence on external refinancing. For Eterna Therapeutics (ERNA), whose revenues from cell engineering licensing have not yet materialized and preclinical expenses remain significant, monitoring short-term liabilities is critical for identifying potential cash flow gaps.